Emricasan (IDN-6556)

Catalog No.S7775 Batch:S777509

Print

Technical Data

Formula

C26H27F4N3O7
Molecular Weight 569.50 CAS No. 254750-02-2
Solubility (25°C)* In vitro DMSO 100 mg/mL (175.59 mM)
Ethanol 25 mg/mL (43.89 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Emricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.
Targets
caspase [1]
In vitro Emricasan, also called IDN-6556 or PF-03491390, is an inhibitor of activated caspases, and it has sub- to nanomolar activity in vitro. Emricasan shows neuroprotective activity for hNPCs but does not suppress ZIKV replication[2].
In vivo Emricasan decreases liver injury but not metabolic derangement in NASH. It also ameliorates inflammation. In the murine NASH model, stellate cell activation and hepatic fibrogenesis are attenuated by administration of the pan-caspase inhibitor Emricasan[1]. Emricasan is currently being evaluated in phase 2 clinical trials for the reduction of hepatic injury and liver fibrosis caused by chronic HCV infection[2].

Protocol (from reference)

Cell Assay:[2]
  • Cell lines

    Astrocytes

  • Concentrations

    9 μM

  • Incubation Time

    1 h

  • Method

    Astrocytes are mock-infected, treated with DMSO or treated with 2 μM niclosamide, 92 μM PHA-690509, 9 μM emricasan, or a combination of 92 μM PHA-690509 and 9 μM emricasan for 1 h before infection with PRVABC59 (MOI = 0.5). Cells are fixed 24 h after infection and stained for ZIKVE and nuclei.
Animal Study:[1]
  • Animal Models

    C57BL/6J mice

  • Dosages

    0.3mg/kg/day

  • Administration

    i.g.

Selleck's Emricasan (IDN-6556) has been cited by 61 publications

The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation [ Immunity, 2024, S1074-7613(24)00221-8] PubMed: 38744293
Neuronal STING activation in amyotrophic lateral sclerosis and frontotemporal dementia [ Acta Neuropathol, 2024, 147(1):56] PubMed: 38478117
ZBP1 causes inflammation by inducing RIPK3-mediated necroptosis and RIPK1 kinase activity-independent apoptosis [ Cell Death Differ, 2024, 31(7):938-953] PubMed: 38849574
Caspase cleavage of RIPK3 after Asp333 is dispensable for mouse embryogenesis [ Cell Death Differ, 2024, 31(2):254-262.] PubMed: 38191748
Hepatocyte-macrophage crosstalk via the PGRN-EGFR axis modulates ADAR1-mediated immunity in the liver [ Cell Rep, 2024, 43(7):114400] PubMed: 38935501
Craniofacial chondrogenesis in organoids from human stem cell-derived neural crest cells [ iScience, 2024, 27(4):109585] PubMed: 38623327
Anti-apoptotic treatment of warm ischemic male rat livers in machine perfusion improves symptoms of ischemia-reperfusion injury [ Heliyon, 2024, 10(8):e29519] PubMed: 38660283
Seed sequences mediate off-target activity in the CRISPR-interference system [ Cell Genom, 2024, 4(11):100693] PubMed: 39510079
Regenerative human liver organoids (HLOs) in a pillar/perfusion plate for hepatotoxicity assays [ bioRxiv, 2024, 2024.03.25.586638] PubMed: 38586058
Reproducible generation of human liver organoids (HLOs) on a pillar plate platform via microarray 3D bioprinting [ bioRxiv, 2024, 2024.03.11.584478] PubMed: 38559126

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.